
PASTEUR2030
France Vaccins Program - Institut Pasteur at the Forefront of Vaccine Innovation in France and Europe
Read the statement from the Institut Pasteur’s management following this week’s government announcement regarding the full deployment of the France Vaccins program as part of France 2030:
Dear all,
It is with great pride that we share with you an important milestone for our institution and for the progress of our Pasteur 2030 strategic plan. After several years of sustained groundwork, demanding collaborations, and remarkable collective commitment, the French government has just announced the official launch of the France Vaccins program - a major national initiative, funded at €100 million under the France 2030 plan, designed to equip France with strategic and sovereign capabilities in vaccine research, development, and innovation. Institut Pasteur is among the founding members and plays a central role in the program.
The France Vaccins Program: Ambition and Scope
Launched under the leadership of Inserm, with Institut Pasteur as a founding partner alongside CEA and AP-HP, the program pursues a dual objective: to accelerate the development of vaccines against emerging infectious diseases by supporting the critical stages of the academic-to-clinical pipeline, and to drive innovation through the most advanced technologies (mRNA, artificial intelligence, synthetic biology, and computational modeling). The program is embedded in the international ambition to respond to future epidemics within 100 days.
Eight projects from French public research institutions are already on the roadmap. Three of them are led by Institut Pasteur teams:
- ECD-MOP — a pentavalent vaccine against American arenaviruses (Institut Pasteur Paris);
- NAVIX — intranasal vaccines against seasonal and pandemic influenza viruses (Institut Pasteur Paris, Institut Pasteur Lille, University of Tours);
- ImMuCHIPP — France's first controlled human infection model to rapidly evaluate vaccine candidates with high pandemic potential (Institut Pasteur Paris, AP-HP).
Three Reasons to Celebrate Together
This announcement is both a culmination and a success for the Pasteur community, on several counts.
- It recognizes the excellence of our work in vaccinology, with three out of eight selected projects led by our teams.
- It demonstrates Institut Pasteur's ability to build large-scale public-private partnerships: this program is the result of mutual trust and sustained dialogue with the government and our institutional partners - CEA, AP-HP, Institut Pasteur Lille, and many others - moving beyond the competitive dynamics that too often characterized the field in the past.
- It is fully aligned with the Pasteur 2030 strategic plan, strengthening both our vaccinology research capabilities and our pandemic preparedness framework, two dimensions that map directly onto our first two strategic pillars.
Institut Pasteur: A European Reference in Vaccine Innovation
This achievement within France Vaccins further consolidates an already strong European standing. Since May 2025, Institut Pasteur has been serving as the coordinator of the preclinical pillar of the European Vaccine Hub (EVH), a collaborative hub funded by the European Commission at €102 million over four years. As a founding member of the EVH, Institut Pasteur brings its scientific expertise and plays a central coordination role among the leading French actors in vaccine research and innovation: Inserm, ANRS-MIE, CEA, and AP-HP. France Vaccins and the EVH thus form two complementary levers of the same national and European momentum in favor of breakthrough vaccinology.
For Yasmine Belkaid, President of the Institut Pasteur, "the launch of France Vaccins, and the selection of three projects led by our teams out of the eight chosen, stand as a testament to the excellence of Pasteur's research and to our ambition to make Institut Pasteur a leading player in vaccine innovation, in France and in Europe. This is a source of great pride and a concrete expression of our Pasteur 2030 strategic plan.
I would like to warmly congratulate and extend my heartfelt thanks to the teams who made these results possible:
- Projects coordinators: Guillemette Masse-Ranson, Sylvain Baize, James Di Santo, David Fidock et Jean-Michel Molina;
- The team members involved, in addition to the coordinators listed above, in the selected projects: Milena Hasan, Darragh Duffy, Laurent Essioux, Hugo Mouquet, Anne-Laure Morin, Muriel Vray;
- The teams of the Scientific Affairs Division, and in particular Patrick Trieu-Cuot;
- The teams of the Department of Research Applications and Industrial Relations (DARRI), and in particular Sotiris Missailidis;
- The teams of the Medical Department, and in particular Hélène Laude and Nathalie Jolly;
- The teams of the Communications and Public Affairs Department, and in particular Henri Pitron and Margot Provot.
Finally, I would like to express my deepest gratitude to Stewart Cole and Christophe d'Enfert, who initiated and championed this strategic project in its earliest stages."
